Amgen (AMGN) Accounts Payables (2009 - 2026)
Amgen (AMGN) posted quarterly Accounts Payables of $2.9 billion for Q1 2026, up 21.99% year-over-year from $2.4 billion in Q1 2025, and up 24.0% quarter-over-quarter from $2.4 billion in Q4 2025.
Amgen (AMGN) Accounts Payables (2009 - 2026) Analysis & Trends
Amgen's Accounts Payables history runs 18 years deep, the most recent figure standing at $2.9 billion for Q1 2026.
- In Q1 2026, Accounts Payables rose 21.99% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $2.9 billion (up 21.99% YoY), while the FY2025 annual figure was $2.4 billion, up 24.06% from the prior year.
- Accounts Payables for Q1 2026 stood at $2.9 billion, up from $2.4 billion in the prior quarter.
- The five-year high for Accounts Payables was $3.0 billion in Q2 2025, with the low at $1.2 billion in Q3 2022.
- The 5-year median for Accounts Payables is $1.6 billion (2024), against an average of $1.9 billion.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables declined 5.92% in 2023, then soared 87.05% in 2024.
- Amgen's Accounts Payables stood at $1.6 billion in 2022, then grew by 1.15% to $1.6 billion in 2023, then rose by 20.0% to $1.9 billion in 2024, then advanced by 24.06% to $2.4 billion in 2025, then grew by 24.0% to $2.9 billion in 2026.
- Business Quant data shows AMGN's Accounts Payables at $2.9 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.87 Bn |
| Mar 31, 2026 | 2.94 Bn |
| Dec 31, 2025 | 2.37 Bn |
| Sep 30, 2025 | 2.84 Bn |
| Jun 30, 2025 | 3.01 Bn |
| Mar 31, 2025 | 2.41 Bn |
| Dec 31, 2024 | 1.91 Bn |
| Sep 30, 2024 | 2.15 Bn |
| Jun 30, 2024 | 2.27 Bn |
| Mar 31, 2024 | 1.63 Bn |
| Dec 31, 2023 | 1.59 Bn |
| Sep 30, 2023 | 1.36 Bn |
| Jun 30, 2023 | 1.21 Bn |
| Mar 31, 2023 | 1.32 Bn |
| Dec 31, 2022 | 1.57 Bn |
| Sep 30, 2022 | 1.20 Bn |
| Jun 30, 2022 | 1.26 Bn |
| Mar 31, 2022 | 1.40 Bn |
| Dec 31, 2021 | 1.37 Bn |
| Sep 30, 2021 | 1.17 Bn |